Ashfield will recruit a team of Key Account Managers, Medical Science Liaisons and Clinical Educators structured for the needs of each product and market
Ashfield Engage, part of UDG Healthcare, has been selected by Pacira BioSciences to provide strategic commercialisation services for its non-opioid pain management products in select European countries.
Pacira has partnered with Ashfield to develop a commercial strategy and deliver outsourced operations in European countries including the UK, Germany, Sweden, Austria, Netherlands and Finland.
Ashfield will recruit a team of Key Account Managers, Medical Science Liaisons and Clinical Educators structured for the needs of each product and market.
Discussing the partnership, Eoin McAtamney, VP, International Business Development at Ashfield Engage, said: “Pacira is an extremely action-orientated, patient-centric organization, and its innovative products offer great promise in the European market, particularly given the burden on healthcare providers following the COVID crisis.
“We have created a hyper-targeted, lean solution that is fit for purpose and maximises every key engagement in the commercial journey. Our team is currently working to deliver this multi-country strategy and we are proud of the part we can play at such a pivotal time for Pacira.”
Pacira’s goal is to provide an opioid alternative to as many patients as possible, aspiring to improve patient outcomes and quality of life. The company’s portfolio of non-opioid pain management products includes Exparel (liposomal bupivacaine), a local anesthetic administered at the time of surgery to control postsurgical pain and reduce or eliminate the need for opioids, and the iovera system, a handheld cryoanalgesia device indicated for use in peripheral nerves and osteoarthritis of the knee.